WallStreetZenWallStreetZen

NASDAQ: COGT
Cogent Biosciences Inc Stock Forecast, Predictions & Price Target

Analyst price target for COGT

Based on 6 analysts offering 12 month price targets for Cogent Biosciences Inc.
Min Forecast
$8.00+22.7%
Avg Forecast
$13.67+109.62%
Max Forecast
$20.00+206.75%

Should I buy or sell COGT stock?

Based on 6 analysts offering ratings for Cogent Biosciences Inc.
Buy
Strong Buy
2 analysts 33.33%
Buy
2 analysts 33.33%
Hold
2 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their COGT stock forecasts and price targets.

COGT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-27
lockedlocked$00.00+00.00%2024-02-26
lockedlocked$00.00+00.00%2024-02-26
lockedlocked$00.00+00.00%2024-02-26
lockedlocked$00.00+00.00%2024-02-23
HC Wainwright & Co.
Bottom 2%
2
BuyMaintains$13.00+99.39%2023-12-15

1 of 1

Forecast return on equity

Is COGT forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
37.5%

Forecast return on assets

Is COGT forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

COGT revenue forecast

What is COGT's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$504.8M
Avg 2 year Forecast
$108.2M
Avg 3 year Forecast
$346.4M

COGT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
COGT$6.52$13.67+109.62%Buy
NVAX$4.85$19.00+291.75%Buy
CVAC$3.05N/AN/A
SVRA$4.85$9.25+90.72%Strong Buy
SLRN$6.75$15.20+125.19%Buy

Cogent Biosciences Stock Forecast FAQ

Is Cogent Biosciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: COGT) stock is to Buy COGT stock.

Out of 6 analysts, 2 (33.33%) are recommending COGT as a Strong Buy, 2 (33.33%) are recommending COGT as a Buy, 2 (33.33%) are recommending COGT as a Hold, 0 (0%) are recommending COGT as a Sell, and 0 (0%) are recommending COGT as a Strong Sell.

If you're new to stock investing, here's how to buy Cogent Biosciences stock.

What is COGT's revenue growth forecast for 2025-2027?

(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.

Cogent Biosciences's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast COGT's revenue for 2025 to be $52,455,482,301, with the lowest COGT revenue forecast at $1,101,481,998, and the highest COGT revenue forecast at $103,809,482,604. On average, 3 Wall Street analysts forecast COGT's revenue for 2026 to be $11,247,897,723, with the lowest COGT revenue forecast at $4,988,882,142, and the highest COGT revenue forecast at $18,829,107,355.

In 2027, COGT is forecast to generate $35,992,067,319 in revenue, with the lowest revenue forecast at $14,564,501,583 and the highest revenue forecast at $62,774,082,524.

What is COGT's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: COGT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is COGT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year COGT price target, the average COGT price target is $13.67, with the highest COGT stock price forecast at $20.00 and the lowest COGT stock price forecast at $8.00.

On average, Wall Street analysts predict that Cogent Biosciences's share price could reach $13.67 by Feb 27, 2025. The average Cogent Biosciences stock price prediction forecasts a potential upside of 109.62% from the current COGT share price of $6.52.

What is COGT's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: COGT) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.